These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33124527)

  • 21. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer.
    Zhang H; Qin C; An C; Zheng X; Wen S; Chen W; Liu X; Lv Z; Yang P; Xu W; Gao W; Wu Y
    Mol Cancer; 2021 Oct; 20(1):126. PubMed ID: 34598686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RNA editing in human cancer: review.
    Skarda J; Amariglio N; Rechavi G
    APMIS; 2009 Aug; 117(8):551-7. PubMed ID: 19664125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR/Cas9-mediated noncoding RNA editing in human cancers.
    Yang J; Meng X; Pan J; Jiang N; Zhou C; Wu Z; Gong Z
    RNA Biol; 2018 Jan; 15(1):35-43. PubMed ID: 29028415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme.
    Mukhopadhyay D; Anant S; Lee RM; Kennedy S; Viskochil D; Davidson NO
    Am J Hum Genet; 2002 Jan; 70(1):38-50. PubMed ID: 11727199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Relevance of Noncoding Adenosine-to-Inosine RNA Editing in Multiple Human Cancers.
    Gu T; Fu AQ; Bolt MJ; White KP
    JCO Clin Cancer Inform; 2019 Jun; 3():1-8. PubMed ID: 31162949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GPEdit: the genetic and pharmacogenomic landscape of A-to-I RNA editing in cancers.
    Ruan H; Li Q; Liu Y; Liu Y; Lussier C; Diao L; Han L
    Nucleic Acids Res; 2022 Jan; 50(D1):D1231-D1237. PubMed ID: 34534336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In cancer, A-to-I RNA editing can be the driver, the passenger, or the mechanic.
    Ganem NS; Ben-Asher N; Lamm AT
    Drug Resist Updat; 2017 May; 32():16-22. PubMed ID: 29145975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A-to-I RNA editing of BLCAP promotes cell proliferation by losing the inhibitory of Rb1 in colorectal cancer.
    Han F; Hu M; Zhang L; Fan X; Wang J; Lou Z; Wang S; Chen L; Ye Y; Ding Y; Jiao H
    Exp Cell Res; 2022 Aug; 417(2):113209. PubMed ID: 35605649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection and Application of RNA Editing in Cancer.
    Qian M; Spada C; Wang X
    Adv Exp Med Biol; 2018; 1068():159-170. PubMed ID: 29943303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computational detection and functional analysis of human tissue-specific A-to-I RNA editing.
    He T; Wang Q; Feng G; Hu Y; Wang L; Wang Y
    PLoS One; 2011 Mar; 6(3):e18129. PubMed ID: 21448465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does RNA editing play a role in the development of urinary bladder cancer?
    Zilberman DE; Safran M; Paz N; Amariglio N; Simon A; Fridman E; Kleinmann N; Ramon J; Rechavi G
    Urol Oncol; 2011; 29(1):21-6. PubMed ID: 19186082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of post-transcriptional RNA editing events.
    Picardi E; D'Erchia AM; Gallo A; Pesole G
    Methods Mol Biol; 2015; 1269():189-205. PubMed ID: 25577380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR-Cas13 System as a Promising and Versatile Tool for Cancer Diagnosis, Therapy, and Research.
    Palaz F; Kalkan AK; Can Ö; Demir AN; Tozluyurt A; Özcan A; Ozsoz M
    ACS Synth Biol; 2021 Jun; 10(6):1245-1267. PubMed ID: 34037380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome sequence-independent identification of RNA editing sites.
    Zhang Q; Xiao X
    Nat Methods; 2015 Apr; 12(4):347-50. PubMed ID: 25730491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers.
    Han L; Diao L; Yu S; Xu X; Li J; Zhang R; Yang Y; Werner HMJ; Eterovic AK; Yuan Y; Li J; Nair N; Minelli R; Tsang YH; Cheung LWT; Jeong KJ; Roszik J; Ju Z; Woodman SE; Lu Y; Scott KL; Li JB; Mills GB; Liang H
    Cancer Cell; 2015 Oct; 28(4):515-528. PubMed ID: 26439496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNA editing affects cis-regulatory elements and predicts adverse cancer survival.
    Wu YM; Guo Y; Yu H; Guo T
    Cancer Med; 2021 Sep; 10(17):6114-6127. PubMed ID: 34319007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human BLCAP transcript: new editing events in normal and cancerous tissues.
    Galeano F; Leroy A; Rossetti C; Gromova I; Gautier P; Keegan LP; Massimi L; Di Rocco C; O'Connell MA; Gallo A
    Int J Cancer; 2010 Jul; 127(1):127-37. PubMed ID: 19908260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RNA editome imbalance in hepatocellular carcinoma.
    Qi L; Chan TH; Tenen DG; Chen L
    Cancer Res; 2014 Mar; 74(5):1301-6. PubMed ID: 24556721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A-to-I editing sites are a genomically encoded G: implications for the evolutionary significance and identification of novel editing sites.
    Tian N; Wu X; Zhang Y; Jin Y
    RNA; 2008 Feb; 14(2):211-6. PubMed ID: 18094120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular diversity through RNA editing: a balancing act.
    Farajollahi S; Maas S
    Trends Genet; 2010 May; 26(5):221-30. PubMed ID: 20395010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.